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EDITORIAL REVIEW
Parathyroid hormone and 1 ,25(OH)2D3 in chronic renal failure
Maintenance of normal calcium homeostasis and the ability
to adapt to abnormal calcium states are dependent on two
hormones and three major organ systems. Parathyroid hormone
(PTH) and I ,25(OH)2D3 (the active form of vitamin D) interact
with the kidney and bone or gut and bone, respectively [1].
Vitamin D3 (cholecalciferol) is a 9,10-secosterol formed by
splitting the B ring of 7-dehydrocholesterol in a photochemical
reaction in the skin [1]. Cholecalciferol is then metabolized in
the liver to 25(OH)D3 and in the kidney through the 1-alpha-
hydroxylase enzyme to l,25(OH)2D3 [2]. PTH increases cal-
cium reabsorption by the renal tubule while l,25(OH)2D3 in-
creases intestinal calcium absorption. In concert, these hor-
mones mobilize calcium from bone into the extracellular fluid
and contribute to the relative constancy of the plasma calcium.
In addition, PTH increases 1-alpha-hydroxylase enzyme activ-
ity in the kidney, thereby increasing the levels of 1 ,25(OH)2D3
in the circulation. A rise in plasma calcium feeds back on the
parathyroid gland to decrease the secretion of PTH. Recent
data suggest that I ,25(OH)2D3 may also directly suppress the
production of hormone by the parathyroid gland [3]. A com-
plete physiologic loop is thus present in which the two hor-
mones interact not only with their classical target organs, but
also with the synthesis of each other (Fig. I).
The classic theory
The relationship between PTH, l,25(OH)2D3, calcium, and
phosphorus in chronic renal failure is complex and our under-
standing of it still incomplete. What is clear is that levels of
circulating PTH become elevated early in renal disease and
often continue to increase pan passu with the decline in renal
function [4, 5]. Although the actual increase in the serum PTH
levels may vary from mild elevations to concentrations many
times the upper limit of normal [6, 7], nearly all renal failure
patients show some degree of hyperparathyroidism. Since the
major control of parathyroid gland function is plasma calcium,
the classical explanation for secondary hyperparathyroidism
has been the "trade-off hypothesis" [8—10], which relates
inappropriate stimulation of parathyroid secretion and hyper-
plasia to a postulated small but significant decrease in plasma
calcium caused by phosphate retention as the filtered load of
phosphate declines. The high level of PTH, with its concomi-
tant effects in multiple systems, is considered by this theory to
be the homeostatic adjustment necessary for the remaining
nephrons to be able to excrete a greater fraction of filtered
phosphate as renal functional declines [8, 10].
This hypothesis has a certain amount of experimental sup-
port. There is definitely a tendency for patients to remain in
phosphate balance until the glomerular filtration rate is less than
20 to 25 mI/mm [11]. The fractional excretion of phosphorus
rises progressively in chronic renal failure as renal function
declines [12, 13], and it has been shown to be proportional to
the level of PTH [14], consistent with a relationship to renal
phosphate balance.
Although plasma calcium levels rather than phosphate levels
have been shown to be associated directly with short-term
changes in PTH secretion, [15], there is abundant evidence that
the state of phosphorus balance can induce or prevent second-
ary hyperparathyroidism. Chronic phosphate loading has led to
increased PTH levels in animals with normal renal function,
although total serum calcium and phosphorus levels remained
normal [16, 17], and acute phosphate administration can lower
serum calcium and elevate PTH in man [18, 19]. Maintaining
phosphate intake constant as renal function declines is associ-
ated with progressive increases in PTH [10, 20], while propor-
tional phosphate restriction has been shown to prevent hyper-
parathyroidism [20—22].
The mechanism by which phosphate affects PTH secretion is
uncertain. The phosphaturia in patients with chronic renal
failure decreases with phosphate restriction weeks before PTH
levels fall [23]. Patients or animals with chronic renal failure do
not have consistently elevated plasma phosphate or low plasma
calcium until late in the course of the disease [11, 13, 14, 23],
which supports the concept that ionized, rather than total,
calcium, may be the important factor [24]. An in vitro study of
the calcium-phosphorus interaction in serum and aqueous so-
lutions failed to demonstrate a significant fall in ionized calcium
upon addition of phosphate [25]. However, one study in dogs
[26] and one in patients [27] have shown a relationship between
serum ionized calcium and dietary phosphorus intake (while
total calcium remained normal) in subjects with renal failure.
The ionized calcium levels increased after phosphate restric-
tion. These findings suggest that phosphate may lower ionized
calcium in vivo.
An additional mechanism for the role of ionized calcium in
the development of secondary hyperparathyroidism has been
elucidated by Brown et at [28]. They examined cells from
excised parathyroid tissue of patients with primary and second-
ary hyperparathyroidism and found that it required a signifi-
cantly higher ambient calcium concentration to suppress PTH
secretion in tissue from patients with primary and secondary
hyperparathyroidism than normal. This increase in the "set
point" for parathyroid suppression may also explain in part the
high PTH levels seen in uremic patients with normal serum
calcium.
Possible roles of vitamin D metabolites
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More recently, recognition of the role of 1,25(OH)2D3 as a
second key hormone in the control of calcium and phosphorus
metabolism has given rise to more complex theories. Studies of
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Fig. 1. Schematic , epresentation of the interrelationship between pro-
duction of PTH and /,25(OH2D3: The physiologic loop.
I ,25(OH)2D3 in advanced renal failure have shown significant
decreases in the serum levels of this hormone (Table 1) [29—34].
In some patients with end-stage renal disease, the active
vitamin D metabolite is undetectable. These observations led to
the concept that 1 ,25(OH)2D3 deficiency may also play a role in
secondary hyperparathyroidism, either by decreasing intestinal
absorption of calcium and thus lowering plasma calcium or by
blunting PTH-induced calcium mobilization from bone.
Skeletal resistance to the calcemic effect of PTH in patients
with renal failure was first described in 1966 [35]. If a normal
level of PTH is incapable of maintaining a normal serum
calcium, the hypocalcemia could stimulate further PTH release.
PTH resistance has been described in patients with both severe
[36] and moderate [37] renal failure. It was first attributed to a
decrease in 1,25(OH)2D3 by Massry et al [381, who suggested
that inadequate activated vitamin D levels led to decreased
intestinal uptake of calcium, hence decreasing the ionized
calcium and stimulating PTFI release. They also noted that in
acutely uremic dogs the rise in serum calcium following PTH
infusion was blunted but that administration of I ,25(OH)2D3
partially corrected the response [38]. A subsequent study
showed complete reversal of the skeletal resistance when
24,25(OH)2D3 was given as well as l,25(OH)2D3 [39]. Somer-
ville and Kaye [401 found no improvement in the calcemic
response to PTH in acutely uremic rats with 1 ,25(OH)2D3 but
some correction when the rats were chronically uremic. They
were subsequently able to correlate the resistance to PTH with
the degree of phosphate retention [41]. There is also in vitro
evidence that PTH can cause bone resorption even in the total
absence of 25(OH)D3 or 1 ,25(OH)2D3 [42].
An alternative explanation for skeletal resistance to PTH is
that persistently high circulating levels of the hormone may in
some way decrease the response of the target tissues. Such a
phenomenon has been seen in patients with primary hyperpara-
Table 1. Serum I ,25(OH)2D3 levels in moderate to severe chronic
renal failure in adults
GFR
mi/mm
l,25(0H2D3
(pg/mi) PTH Reference
ND 13±5.0
(normal 26—58)
ND 29
ND <5
(normal 2 1—45)
ND 30
15.5 2 19 2.1
(normal 34 1.5)
Increased
NK
31
ND 9.0 3.9
(normal 12.1—70.3)
Increased
C-terminal
32
<35 "Low"
(no values given)
Increased
NK
33
5-35 17.7 (0—34.5)
(normal 13.2—47.6)
Increased
C-terminal
N-terminal
34
Abbreviations are: ND, not done; NK, not known; C-terminal,
carboxy-terminal radioimmunoassay; N-terminal, amino-terminal radi-
oimmunoassay.
a Level and type of assay.
thyroidism [43]. Several in vitro studies also support this
hypothesis. Olgaard et al found that release of cyclic 3',5'-
adenosine monophosphate (cAMP) from isolated perfused bone
in response to infused PTH was attenuated in both acute [44]
and chronic [45] renal failure. PTH-induced release of cAMP
returned to normal following thyroparathyroidectomy in both
studies. Exposure of cultured embryonic bone cells to high
levels of PTH leads to down-regulation of the cells' PTH
receptors [46]. A recent report by Galceran et al on chronically
uremic dogs [47] showed that I ,25(OH)2D3 had no effect on the
resistance of bone to PTH, but instead related the resistance to
skeletal desensitization by the high ambient levels of PTH.
However, this hypothesis has not been tested in man, and many
studies support some role for vitamin D in mobilization of
calcium by PTH.
Inhibition of PTH by 1,25(OH)2D3
A number of studies have suggested that I ,25(OH),D3 exerts
feedback on the parathyroid glands, but the direction of the
effect and its magnitude have been confusing [48—501. Recent
studies have clarified the mechanism and details of this effect.
Using cultured parathyroid cells and a cloned cDNA probe for
pre-proPTH, our laboratory showed that I ,25(OH),D1 decreased
levels of pre-proPTH mRNA in a specific, reversible, and dose-
responsive fashion from physiologic (10- 'M) to pharmacologic
levels (10 M) [5 I]. The effects were most prominent with
1 ,25(OH)2D3, followed by 24,25(OH)2D3 and 25(OH)D3, the
same sequence for the effects of vitamin D metabolites in other
tissues.
We have recently shown that the effect of 1 ,25(OH)2D3 is
directly on gene transcription, using "nuclear runoff" tech-
niques in which the synthesis of pre-proPTH mRNA was
altered as early as one to two hours after exposure to I,
25(OH)2D [52]. Although the primary effect appears to be on
mRNA transcription, an effect of l,25(OH)2D3 on mRNA
half-life has not yet been ruled out. Cantley et al [3] showed a
close correlation between the decrease in PTH release and the
decrease in mRNA. There was no acute effect of I ,25(OH)2D
1 ,25(OH)2D3
Relationships of
calcium, PTH and 1,25(OH)2D3
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Table 2. Serum I ,25(OH)2D1 levels in mild-moderate chronic renal
failure in adults
Serum
GFR
mi/mm
creat
mg/di
I ,25(OH)2D1
pg/mi PTH Reference
50—80 1.5—3.5 44 3.7
(normal 34 1.5)
Increased
NK
31
ND 3.2 0.4 21.8 3.8
(normal 12—70)
Increased
C-terminal
32
26—63 ND 10.02 8.61
(normal 18—48)
Increased
C-terminal
59
35—55 ND "Normal"
(no values given)
Increased
NK
33
ND 3.43 3.1 29.4 2.6
(normal 33.8 1.2)
Increased
Mid-molecule
57
30—80 2.16 0.19 51.5 10.5
(normal4l.1 5.7)
Increased
C-terminal
58
38—78 ND 16 3
(normal 39 5)
Increased
C-terminal
60
55—65 ND 43.5—74.5
(normal 20.9—41.9)
Increased
N-terminal
27
27—73 ND 18.8 12.8
(normal 29.1 8)
Increased
C-terminal
61
Abbreviations are: ND, not done; NK, not known; C-terminal,
carboxy-terminal radioimmunoassay; N-terminal, amino-terminal radi-
oimmunoassay; Mid-molecule, middle-molecular radioimmunoassay.
Level, type of assay.
on PTH secretion. It appears that 1 ,25(OH),D3 exerts its
primary effect by inhibiting transcription of DNA, thereby
decreasing the synthesis of PTH available for secretion. Con-
versely, a decrease in the level of I ,25(OH)2D3 would increase
the synthesis and secretion of hormone by the cell. Since
physiologic levels of l,25(OH)2D1 (10H M) decrease PTH
synthesis, these findings suggest a suppressive effect of normal
levels of I ,25(OH)2D3 on P1'H synthesis and secretion.
Circulating levels of calcium and I ,25(OH)2D are thus both
important in controlling PTH secretion in chronic renal failure.
The relative contribution of each regulator to secretion and
hyperplasia remains to be determined. Parenterally adminis-
tered I ,25(OH)7D3 lowers PTH levels in hemodialysis patients
far more effectively than calcium, even if both substances raise
ionized calcium levels comparably [531. Intraperitoneal admin-
istration of l,25(OH)7D is more effective than high dialysate
calcium in suppressing PTH in peritoneal dialysis patients [54].
A study in the dog showed that hyperparathyroidism develops
in chronic renal failure, even when ionized calcium levels are
kept elevated by a high calcium intake, if levels of I ,25(OH),D3
are allowed to fall [551. Administration of l,25(OH)D prevents
this rise in PTH. On the other hand, the same investigators have
found that uremic dogs on a low phosphate diet did not develop
hyperparathyroidism despite a 66% fall in l,25(OJ-I)2D3; this
regimen led to an increase in ionized calcium [26]. Hence, while
vitamin D is important, it is balanced by changes in calcium and
possibly other factors, such as magnesium, which would sup-
press secretion [56].
Early chronic renal failure
The pathogenesis of secondary hyperparathyroidism in pa-
tients with mild to moderate renal failure is less clear than in
Table 3. Serum l,25(OH)2D1 in children with renal disease
GFR 1 ,25(OH)2D1
mi/min/1.73 pg/mi PTH Reference
Study 1 Normal 54 4 63
25—50 32 4 Increased
C-terminal
On hemodialysis 10 2 Markedly
increased
Study 2 64
Normal 43 12
75—150
0—48
48 16
16 12
ND
ND
Abbreviations are: ND, not done; C-terminal, carboxy-terminal
radioimmunoassay.
advanced renal failure. In 1978 Slatopolsky et al reported that
patients with glomerular filtration rates between 50 and 80
mI/mm had serum I ,25(OH)7D1 levels that were, if anything,
somewhat higher than those in normal controls [311. Despite
this finding, serum PTH was elevated in all patients. There have
been eight subsequent studies measuring vitamin D metabolites
in patients with early renal failure which confirm the early
development of hyperparathyroidism (Table 2). Five of these
found normal or elevated levels of I ,25(OH)2D in early renal
failure [27, 32, 33, 57, 58]. In contrast, three studies reported a
significant decrease in mean serum l,25(OH)2D3 levels in early
renal failure [59—61]. All three included one or more patients
with a glomerular filtration rate below 40 mI/mm (complete
individual data are not given); this may have lowered the mean
value, since prior studies considered early renal failure to mean
a glomerular filtration rate above 40 mI/mm [22, 62]. In addition,
serum I ,25(OH)2D3 values were within the normal range in 3 of
17 patients in the first study [59], 2 of 5 patients in the second
study [60], and 17 of 41 patients in the third study [61]. These
results imply a probable heterogeneity in the ability of kidneys
in mild to moderate renal failure to hydroxylate 25(OH)D3 in the
one position. There may also be some discrepancy among the
different studies due to differences in the methodology for
l,25(OH)2D assays. Furthermore, there is considerable heter-
ogeneity in the assays for PTH (Tables I to 3). Historically,
most of the studies in renal failure used carboxy-terminal
assays, which also measure inactive and accumulated hormone
fragments [I]. More meaningful data in renal failure depend on
measuring amino-terminal or intact PTH with the newer assays.
PTH and 1,25(OH)2D3 levels in children
The above studies were performed on adult patients. There
are two papers on I ,25(OH)7D3 in children with chronic renal
disease (Table 3). Both appear to show a diminution in activated
vitamin D levels even in moderate renal insufficiency. Portale et
al [63] reported the mean serum level of I ,25(OH)2D3 to be
reduced by 40% in children with glomerular filtration rates of 25
to 50 mI/mm/I .73 a statistically significant difference. Ches-
ney et al [64] found normal levels of I ,25(OH),D3 in children
with renal disease whose glomerular filtration rates were be-
tween 75 and 150 ml/min/I.73 M2. This could be interpreted to
mean that children, who are growing and have a greater skeletal
demand for activated vitamin D, develop a deficiency of the
hormonal metabolite earlier in the course of renal failure than
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adults. However, seven of the eight patients in the study by
Portale et al [631 had tubulointerstitial disease, which may
preferentially destroy the tissue containing the 1-alpha-hydrox-
ylase (although in the adult studies of early renal failure that
specified the disease [27, 57], the presence or absence of
tubulointerstitial disease did not appear to affect I ,25(OH)2D3
levels). More important, neither study included children with
glomerular filtration rates between 50 and 75 mI/mm/i .73 M2, so
the question of early renal failure in children may not yet have
been addressed fully.
Interaction between PTH and vitamin D: The role of phosphate
Six studies report that in many adult patients with chronic
renal failure, hyperparathyroidism often antedates any detect-
able fall in l,25(OH)2D3 levels [27, 31—33, 57, 581. What role,
then, do vitamin D and its metabolites play in the development
of secondary hyperparathyroidism in this phase? Llach and
Massry studied this question in four patients with creatinine
clearances between 55 and 65 mI/mm [27]. There were mild to
moderate elevations of 1 ,25(OH)2D3, normal levels of the other
vitamin D metabolites, and low levels of ionized calcium. PTH
was substantially elevated, with a mean nearly twice the upper
limit of normal. These findings were similar to those reported by
Cremer et al in 10 patients with mild to moderate renal failure
[58]. Although serum phosphate levels were in the normal range
and did not change throughout the study, restriction of phos-
phate intake in these patients led to normal levels of PTH, a
marked increase in the I ,25(OH)2D3 levels to nearly twice the
upper limit of normal, and an increase in ionized calcium to
normal. Further elevation of 1,25(OH)2D3 led to improved
intestinal calcium absorption and a greater calcemic response to
infused PTH. A recent study suggests that in early renal failure
the higher the dietary phosphorus intake, the lower the serum
l,25(OH)2D3 level [61]. Portale et al [631 also noted a rise in
1,25(OH)2D3 levels and a fall in serum PTH in children with
renal failure whose phosphate intake was restricted. These
findings imply a pivotal role for phosphate in the control of both
PTH and 1 ,25(OH)2D3 and as a mediator of the interaction
between these hormones. Phosphate may act to inhibit PTH-
induced calcium elevation in human renal failure, either by
interfering directly with the response of bone to PTH or by
affecting PTH-vitarnin D interaction in bone [621. In fact, as
stated above, restriction of phosphate intake has been shown to
lower serum PTH levels in uremic animals even when 1,
25(OH)2D3 [261 or serum ionized calcium [55] falls.
The rise in 1 ,25(OH)2D3 that accompanies phosphate restric-
tion suggests that phosphorus may control the activation of
vitamin D. Many studies, as noted above, have shown that
serum phosphorus remains normal in early chronic renal fail-
ure, often in the low normal range. Hence, there must be
intracellular phosphate retention, which is reasonable, consid-
ering phosphate is the major intracellular anion. Tanaka and
DeLuca [651 have demonstrated that the intracellular phosphate
content of kidney cortical cells is a major control mechanism for
the renal hydroxylation of 25(OH)D3. Levels of phosphorus
below 300 .tg/g of tissue are associated with the production of
1 ,25(OH)2D3 as the major metabolite, while phosphorus content
above 400 g/g of tissue causes predominantly 24,25(OH)2D3 to
be produced.
What enables patients to maintain a normal level of 1,
25(OH)2D3 in the face of a diminished nephron mass? Llach [661
has proposed that the high level of PTH causes excess stimu-
lation of the renal cortex, leading to increased 1-hydroxylation
of vitamin D per remaining nephron. On the other hand, Taylor
et al [67] have shown that rats undergoing unilateral nephrec-
tomy maintain normal levels of l,25(OH)2D1 despite the 50%
reduction in renal mass and that this remains true even after
thyroparathyroidectomy. The nephrectomized rats did have
lower plasma phosphate levels; hence lower renal cell phos-
phate might be a factor, but the difference was small. Although
residual renal function and the degree of compensatory hyper-
trophy were not measured in the nephrectomized animals, this
work suggests that there are additional mechanisms indepen-
dent of PTH which induce the remaining renal tissue to increase
its production of I ,25(OH)2D1. A recent animal study suggests
that lowering nephron mass leads to diminished synthesis of
l,25(OH)2D3 and that levels remain normal due to decreased
renal metabolic clearance of this hormone [68]. However, the
kidney normally excretes only about 14% of the l,25(OH)2D3 in
man [2]. Clearly, this area needs further investigation.
Receptors for 1 ,25(OH)2D3
Like its sister steroid hormones, I ,25(OH)2D1 appears to act
through a receptor protein. These proteins are tissue-specific,
have a high affinity for the steroid and are "activated" when
they bind the steroid. The activated steroid-receptor complex
accumulates in the nucleus and binds a specific regulatory
region of the 5'-flanking sequence of affected genes, altering
DNA transcription of specific precursor-messenger RNA (mRNA)
molecules [691. Alteration in the synthesis of critical proteins
and, in some cases, changes in cell differentiation, complete the
effects of the steroid.
There is now evidence that the link between I ,25(OH)2D3 and
parathyroid function is at the level of the receptor. A specific
avian I ,25(OH)2D1 receptor protein has been isolated and
characterized [70]. The avian receptor is 60,000 daltons and
contains a portion that binds I ,25(OH)2D3 (near its C-terminus)
and a zinc-stabilized DNA binding domain near the N-terminus.
Mammalian receptors are somewhat smaller. In addition to
expected receptors for vitamin D in the gut and bone, known
target organs for the hormone, receptors have been identified in
a number of other tissues not normally known to be sites of
vitamin D action, including the parathyroid gland. Initial studies
by Henry and Norman [711 demonstrated in vivo localization of
labeled I ,25(OH)2D3 in rachitic chick parathyroid glands at
concentrations nearly equal to that of intestinal cells. Hughes
and Haussler [72] demonstrated a specific I ,25(OH)2D1 receptor
in chick parathyroid cytosol and nuclear chromatin with an
apparent molecular weight similar to that of the intestinal
receptor. The parathyroid receptor has now been found in
mammalian parathyroid glands as well, including those of the
pig and man [70].
The biologic significance of the parathyroid vitamin D recep-
tor has until recently been unclear. Earlier attempts to deter-
mine whether l,25(OH)2D3 and other vitamin D metabolites
regulated acute PTH secretion produced very contradictory
results, including evidence that 1,25(OH)2D3 increased, de-
creased and had no effect on PTH release. More recent studies
have examined longer-term effects of vitamin D, recognizing
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the fact that steroid hormone effects may not be immediate [68].
Studies by Au of rat parathyroid glands in organ culture [731 and
by Cantley et a! [31 in primary cultures of bovine parathyroid
cells showed that 24 to 48 hours of exposure to 1 ,25(OH)2D3
were necessary before there was a decrease in PTH release.
Similar findings have been noted by Chan et al [74].
Merke et al [751 have described an additional mechanism
relating secondary hyperparathyroidism to vitamin D in chronic
renal failure. In rats made uremic six days after subtotal
nephrectomy, the authors found increased parathyroid gland
weight (303 vs. 160 sg) and decreased levels of l,25(OH)2D3
(59.8 vs. 121 pg/mI). Using competitive binding assays and
Scatchard analysis, the authors found a significant decrease in
the specific binding capacity of the 'uremic" parathyroid
glands for I ,25(OH)2D3 compared with control. Although spe-
cific binding was decreased, there was no evidence for a
decrease in the affinity constant for individual receptors or
change in size of the receptor. A similar study in man has been
done by Korkor [761, who examined I ,25(OH),D3 receptors in
parathyroid glands excised for primary and secondary hyper-
parathyroidism. The binding of l,25(OH),D3 to receptors for
the hormone in parathyroid glands from uremic patients was
substantially lower than similar determinations in parathyroid
adenomas. The binding was inversely proportional to the serum
creatinine and was higher in patients who had received renal
transplants and needed parathyroidectomy post-transplant.
The above findings are intriguing, but it will be necessary to
demonstrate reversal of these abnormalities after correction of
uremia in order to support more completely the concept of
regulation of receptor number in the parathyroid. The mecha-
nism for the decrease in specific binding was not determined,
nor was the point in the course of renal failure when the
l,25(OH)2D3 binding decreases identified. Both the animal and
human studies involved parathyroid glands from individuals
with advanced renal failure, and there were no controls from
normal human glands [77]. An additional area for study is
whether the decrease in vitamin D receptor binding may be
related to the increased calcium "set point" of PTH suppres-
sion in uremic parathyroid glands or other cellular factors [28].
Aluminum retention and hyperparathyroidism
Developments over the past four years have brought to light
yet another factor affecting the parathyroid vitamin D-bone
axis: aluminum retention [781. Patients with chronic renal
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failure often retain aluminum, both from the phosphate binding
gels they take [79—821 as well as from the local water supply
83]. Aluminum causes osteomalacia by depositing along the
mineralization front of bone in chronic dialysis patients [841. It
was initially noted that these patients had low blood levels of
parathyroid hormone [85]. Two subsequent clinical studies
have shown that uremic patients with aluminum-associated
osteomalacia have a markedly blunted rise in plasma PTH level
when hypocalcemia is induced by low calcium dialysis [86, 87].
A number of studies have shown that aluminum can block the
release of PTH from parathyroid tissue in vitro [88, 891 and that
this effect is dose-related [901. Removal of accumulated alumi-
num from dialysis patients leads to a rise in serum levels of both
PTH and l,25(OI-I)2D3 [911. It has also been reported recently
that bone in aluminum-loaded uremic animals is substantially
less responsive to injected PTH than that of comparably uremic
animals not given aluminum [92, 93].
Different scenarios for early and late renal failure
The current data suggest, therefore, that there are probably at
least two possible scenarios for the development of secondary
hyperparathyroidism—one for early and one for late chronic
renal failure—with phosphorus, ionized calcium, and I ,25(OH)2D3
playing a role in both. Figure 2 shows a possible chain of events
for early chronic renal failure. Reduced nephron mass and
glomerular filtration rate could lead to phosphate retention,
primarily intracellular, which lowers serum ionized calcium and
decreases 1-hydroxylation of 25(OH)D1. This is counterbal-
anced by increased secretion of PTH, which stimulates 1-alpha-
hydroxylation. There may also be a decrease in renal metabolic
clearance of activated vitamin D, so that I ,25(OH)2D5 levels
remain normal and thus only partially suppress the rise in PTH
caused by the decreased ionized calcium level. Phosphate
restriction will permit a rise in ionized calcium and enhance
l,25(OH)2D3 synthesis, leading to a rise in 1 ,25(OH)2D3 and
ionized calcium, hence suppressing parathyroid activity.
Figure 3 shows the proposed sequence in moderate to severe
chronic renal failure. Here, a more marked reduction in neph-
ron mass and glomerular filtration rate leads to both intracellu-
lar and extracellular phosphate retention, with marked suppres-
sion of l,25(OH)2D3 as well as lower plasma calcium. Simulta-
neously, the uremic state could lead to parathyroid hyperplasia
and a decrease in the sensitivity of the parathyroid glands to the
ambient ionized calcium level (altered set point) and reduced
binding of I ,25(OH)2D3 by the parathyroid gland receptors. The
lower 1 ,25(OH)2D3 level and its diminished effectiveness as an
inhibitor, combined with the phosphate-induced fall in calcium,
produce a more marked elevation of plasma PTH. The latter
effect may be blunted due to the inhibition of PTH release by
retained magnesium and aluminum, the latter decreasing the
effect of PTH on bone. Factors that cause resistance of bone to
the action of PTH enhance the decrease in plasma calcium. A
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decrease in renal catabolism of PTH may also help to maintain
elevated levels of this hormone in severe chronic renal failure,
although it is not certain that it increases biologically active
PTH further [941.
Implications for management
What do these findings imply for the management of patients
with chronic renal failure? A synthetic form of l,25(OH)2D3
(calcitriol) is now available, and when given intravenously or
intraperitoneally, it can suppress hyperparathyroidism in dial-
ysis patients [54, 55]. A new study in the dog suggests that
1 ,25(OH)2D administration may prevent aluminum accumula-
tion in bone [95]. l,25(OH)2D3 has been given to patients with
moderate chronic renal failure and has lowered their PTH levels
with occasional reversible hypercalcemia but without other side
effects [33, 96]. However, there are several studies by Chris-
tiansen et al [34, 97, 98] showing that in some chronic renal
failure patients not on dialysis (creatinine clearance 5 to 35
mi/mm), vitamin D analogues may hasten the progression of
renal dysfunction. The other studies do not show this effect, but
caution in using these agents in patients not on dialysis would
seem prudent.
Since, as two studies have shown, restriction of phosphate in
chronic renal failure can by itself cause a rise in endogenous
l,25(OH)2D3 to nearly twice the upper limit of normal, with a
concomitant decrease in PTH levels [27, 48], this would be the
first logical intervention in trying to prevent secondary hyper-
parathyroidism. Elevations of serum PTH occur quite early in
chronic renal failure, so phosphate restriction should probably
be instituted when the renal failure is mild, perhaps when the
glomerular filtration rate falls below 60 to 70 ml/min. Restriction
of dietary protein is associated with a decrease in phosphorus
intake, but this usually needs to be supplemented with a
phosphate binding agent. In order to minimize the burden of
aluminum accumulation in the patient, calcium carbonate may
be tried as a first-line agent to prevent intestinal absorption of
dietary phosphate before aluminum salts are prescribed [99,
1001. Should phosphate restriction alone fail to restore a normal
PTH level, or if osteomalacia is diagnosed, calcitriol can be
given, with careful monitoring of serum calcium and residual
renal function. It is not yet certain how early parathyroid
hyperplasia occurs, but this could be a key factor in the
dynamics of abnormal calcium homeostasis.
Conclusions
A number of different factors may affect the development of
secondary hyperparathyroidism in chronic renal failure, but the
most important ones regulating PTFI secretion seem to be
serum ionized calcium and levels of 1 ,25(OH)2D3. Whether
these are indeed separate mechanisms or whether they are
linked has yet to be determined. While low calcium increases
PTH secretion [241, it does not increase PTH synthesis in vitro
compared with normal [10]. High calcium, on the other hand,
suppresses PTH synthesis [101]. Studies in patients and animals
have shown that an increase or decrease in serum PTH levels
can be achieved by maneuvers that alter either calcium or
activated l,25(OH),D3 without changing the other. This is
particularly true of phosphate balance. Although the "trade-off
hypothesis" as initially formulated could not take into account
the roles of l,25(OH)2D3 and aluminum in affecting PTH
secretion, it focused attention on the importance of phosphate
balance in generating hyperparathyroidism and in preventing
this complication of renal failure. A more definitive explanation
of the hyperparathyroidism will be forthcoming from future
studies of the receptors and gene action of vitamin D metabo-
lites, calcium, and phosphate in the parathyroid and other target
tissues. Studies not only of the number and affinity of such
receptors, but also of other factors such as phosphate and other
retained metabolites that might affect the interaction between
receptor and ligand, should cast more light on the phenomena of
parathyroid secretion and hyperplasia in renal disease. More
detailed studies of early renal failure, with emphasis on mea-
surements of phosphate balance, ionized calcium, 1 ,25(OH)2D3
and biologically active PTH will be most useful.
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